Pharmaceutical Industry 8 February 2026

Pfizer Just Got a First-of-Its-Kind Breast Cancer Approval. The Bigger Test Comes This Week

Pfizer Inc. and Arvinas scored FDA approval for Veppanu, a breast cancer pill, adding a fresh weapon to Pfizer’s oncology lineup. With this nod, Pfizer gains ground in its push to prove it can replace waning sales from legacy products after the COVID boom.

3 May 2026

NASDAQ:ARVN·NYSE:PFE·Pharmaceutical Industry

Summit Therapeutics Stock Plunges 23%: The Ivonescimab Update Shaking Its Keytruda Challenge

Summit Therapeutics Inc. dropped roughly 23% Friday afternoon after the HARMONi-3 update disappointed—ivonescimab, the biotech’s high-profile lung cancer hopeful, didn’t deliver the early upside investors were hunting for. Shares last traded at $16.60. Merck & Co., running Keytruda as the trial comparator, moved up 3%.

1 May 2026

NASDAQ:SMMT·Pharmaceutical Industry·Stock Market

Esperion Stock Surges On ARCHIMED’s $1.1 Billion Buyout — What Shareholders Get Next

ARCHIMED is buying Esperion Therapeutics Inc. in a transaction valued at up to $1.1 billion, the companies said Friday. Shares of Esperion jumped on the Nasdaq after word got out that the Michigan drugmaker is set to go private.

1 May 2026

Pharmaceutical Industry·Stock Market

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics jumped to secure $500 million through stock and pre-funded warrants Monday, following a spike in its shares after interim results from its investigational psoriasis treatment. The surge also sparked new comparisons to big-name drugs from AbbVie and UCB.

27 April 2026

EBR:UCB·NYSE:ABBV·Pharmaceutical Industry·Stock Market

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics Inc. is heading into a heavy clinical-data stretch with fresh Wall Street backing, after Stifel analyst Paul Matteis initiated coverage of the Nasdaq-listed company with a Buy rating and a $30 price target. The focus is DT120 ODT, an orally disintegrating tablet form of lysergide D-tartrate, better known as LSD, now in late-stage trials for anxiety and depression.

18 April 2026

Biotechnology·NASDAQ:DFNT·Pharmaceutical Industry

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Shares of Hims & Hers Health surged Thursday after the FDA signaled it would review restrictions on certain peptides—a move that’s opened up a new narrative for investors as the telehealth firm shifts focus from promoting compounded GLP-1 drugs. By early afternoon in New York, the stock was changing hands at $26.65, up $2.36 on the day.

16 April 2026

Health News·NYSE:HIMS·Pharmaceutical Industry·Stock Market

ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio was changing hands around $7.42 early Wednesday, matching Tuesday’s close after a sharp 21.1% drop sparked by an FDA warning letter that criticized the company for allegedly making false or misleading claims about its cancer therapy Anktiva. The shares had plunged as much as 26% during Tuesday’s trading.

25 March 2026

NASDAQ:IBRX·Pharmaceutical Industry·Stock Market

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics jumped roughly 18% late Monday morning, rallying alongside other rare-disease biotech stocks after word got out that the FDA’s head of biologics is set to depart next month. uniQure picked up about 15%, while Regenxbio climbed close to 20%.

9 March 2026

NASDAQ:ATRA·NASDAQ:QURE·NASDAQ:RGNX·Pharmaceutical Industry·Stock Market

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Capricor Therapeutics jumped 7.6% to $30.01 early Monday after the company scheduled its fourth-quarter and full-year results for March 12, putting deramiocel—the company’s experimental treatment for Duchenne muscular dystrophy—back in focus. Duchenne is a genetic disorder that causes progressive muscle loss. Capricor plans to publish results after Thursday’s close and will hold its conference call at 4:30 p.m. ET.

9 March 2026

NASDAQ:CAPR·Pharmaceutical Industry

Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now

Day One Biopharmaceuticals opened Monday at $21.24, just under Servier’s $21.50 per share cash offer, with traders watching the French firm’s $2.5 billion acquisition, first unveiled March 6.

9 March 2026

Pharmaceutical Industry

Tango Therapeutics stock jumps 36% after Q4 results, Erasca cancer trial pact

Tango Therapeutics surged about 36% Thursday, propelled by fourth-quarter numbers and news of a fresh partnership with Erasca to study vopimetostat—the company’s lead drug—in pancreatic and lung cancer settings. Shares recently changed hands at $16.83.

6 March 2026

NASDAQ:ERAS·NASDAQ:TANGO·Pharmaceutical Industry·Stock Market

FDA hits Novo Nordisk with another Ozempic ad warning — second strike in weeks

Novo Nordisk A/S has been flagged again by the U.S. Food and Drug Administration, which says a consumer ad for its diabetes star, Ozempic, overstates the drug’s benefits and misleads viewers. It's the Danish company’s second warning about its advertising in less than a month.

4 March 2026

NASDAQ:NVO·Pharmaceutical Industry

AbbVie stock price jumps 3% into weekend as $8 billion bond sale nears settlement

AbbVie Inc shares jumped 3.29% to close at $232.08 on Friday, bucking a three-day slide and outperforming the wider market slump. The S&P 500 lost 0.43%, Dow shed 1.05%. AbbVie not only broke its own losing streak but also left Johnson & Johnson, Pfizer, and Amgen trailing behind.

28 February 2026

NYSE:ABBV·Pharmaceutical Industry·Stock Market

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers Health shares nudged 0.3% higher ahead of Thursday’s open, building on Wednesday’s 2.3% advance. The telehealth firm wrapped up the last session at $15.82, after trading in a range from $15.06 to $16.46 during the day. On Tuesday, the stock had dropped to $13.74.

26 February 2026

NASDAQ:HIMS·NYSE:NVO·Pharmaceutical Industry·Stock Market

Viking Therapeutics stock (VKTX) slips in premarket after 11% rally as Novo obesity-drug stumble hits tape

Viking Therapeutics slipped 0.5% to $34.30 ahead of Tuesday’s open, following an 11.1% surge the day before that took the stock to a $34.46 close. Monday’s range ran from $32.50 up to $35.73, with roughly 5.68 million shares traded.

24 February 2026

NASDAQ:VKTX·Pharmaceutical Industry·Stock Market

CSL share price slips as buyback tally grows; Lilly deal sets up next week

CSL Ltd slipped 0.6% Friday, ending the session at A$153.27. That pullback shaved off some of the gains from a two-day run-up earlier in the week.

20 February 2026

ASX:CSL·NYSE:LLY·Pharmaceutical Industry·Share Buybacks·Stock Market

AbbVie stock set for $1.73 dividend as ABBV heads into Tuesday’s reopen

AbbVie finished Friday at $231.50 per share, gaining 1.8%. U.S. equity trading paused Monday for Washington’s Birthday, with the New York Stock Exchange closed.

16 February 2026

Dividends·NYSE:ABBV·Pharmaceutical Industry·Stock Market

Merck stock price hits a 52-week high on Deutsche Bank upgrade as MRK heads into holiday week

Merck & Co Inc jumped 1.8% to settle at $121.41 on Friday, notching a new 52-week high of $123.33 during the session, after Deutsche Bank bumped its rating and set a $150 price target for the pharma giant. U.S. markets then closed for the weekend.

15 February 2026

NYSE:MRK·Pharmaceutical Industry·Stock Market

Johnson & Johnson stock price: JNJ near 52-week high as talc ruling, heart-device data set up Monday

Johnson & Johnson closed out Friday’s session at $239.99, gaining 0.93%, before edging down 0.12% to $239.70 in after-hours trading. Shares never strayed far from the 52-week high, staying inside a tight $237.98 to $240.93 range.

8 February 2026

NYSE:JNJ·Pharmaceutical Industry·Stock Market

Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next

Roivant Sciences Ltd heads into Monday’s U.S. open after a standout Friday, when shares jumped 22.14% to finish at $25.82. Volume was striking—over 24 million shares traded, crushing the stock’s typical activity.

8 February 2026

NASDAQ:ROIV·Pharmaceutical Industry

Pharmaceutical Industry 8 February 2026 - 3 May 2026